. Primary glioblastomas, which arise de novo, may show epidermal growth factor receptor (EGFR) amplification and PTEN mutations, compared with secondary glioblastomas that progress from lower grade astrocytomas, which occur in younger patients, and typically carry mutations including isocitrate dehydrogenase IDH1/2, which tend to be absent in primary glioblastomas (<5%) showed that increased expression of hBCATc supports tumour growth and highlighted it as a new therapeutic target for glioblastomas.
The hBCATc protein is however one of two isoforms (the other, mitochondrial (hBCATm)) that can catalyse the transamination of the branched-chain amino acids (BCAA) followed by complete oxidation by the branched-chain α-keto acid dehydrogenase complex (BCKDC) . Like BCAT1 (gene encoding hBCATc), a significant up regulation of BCAT2 (gene encoding hBCATm) was reported in IDH-WT tumours (Tönjes et al., 2013) . However, hBCATm expression was not studied at the protein level nor assessed as a prognostic marker for patient survival. It is important to consider hBCATm expression and indeed the expression of the BCKDC in IDH-WT tumours because their existence will also contribute to BCAA metabolism promoting tumour survival. This is of relevance because, if hBCATc was considered the only contributor to BCAA metabolism and thus the sole therapeutic target, then if hBCATm expression was found to be increased in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 5 | P a g e
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Materials and methods
Patient Samples
The study was approved by the Brain Tumour Bank South West Research Ethics Committee, Bristol, UK. For Western blot analysis, 64 glioma tumours with a range of subtypes were compared for BCKDC, hBCATc, and hBCATm expression (Supplementary Table   1 ). For IHC 53 glioma cases were graded by Dr. Kurian, consultant neuropathologist at Southmead Hospital Neuropathology Department, Bristol, UK. All glioma cases had a diagnosis from grade II to IV.
IDH and MGMT analysis
DNA was extracted from fresh, frozen tissue using the BioRobot EZ1 workstation (Qiagen).
Sanger sequencing of the p.Arg132 region of IDH1 (codons 55 -138) and p.Arg172 region of IDH2 (codons 151 -179) was completed using a 3730 DNA analyser (Applied BioSystems). Immunohistochemistry (IHC) was performed using standard techniques with the antibody clone H09 (Dianova), which specifically reacts with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation (1:10 dilution for 30 min at room temperature) in formalin-fixed tissue. MGMT analysis was assessed by methylation sensitive PCR. DNA samples underwent bisulphite modification, followed by PCR using the primers described by Estellier et al 2000 in a diplex reaction. PCR products were separated on the Beckman Coulter CEQ 8000 system.
Immunohistochemistry
Sections (3 µm in thickness) were taken onto 3-aminopropyltriethoxysilane coated adhesive slides and prepared for incubation with antibodies as previously described. 10 
Western blot analysis
For Western blot analysis, 250 mg of tissue was collected in RNase free tubes and probing, membranes were incubated with 1 M NaOH (7 minutes) and washed in TBST.
Statistical analysis
Data validity checks and descriptive analyses were performed prior to inferential analyses.
These preliminary analyses indicated good quality data, free from unusual or aberrant observations, on model fit in a Cox proportional hazards regression. The strength of the association between BCKDC, hBCATc and hBCATm was quantified using Pearson's 7 | P a g e product moment correlation coefficient for linear association and for monotone association using the nonparametric Spearman's rank correlation coefficient. Both approaches gave the same statistical conclusions. Differences in mean levels for each of BCKDC, hBCATm and hBCATc between IDH+ and IDH-was assessed using the robust independent samples t-test without assuming equality of variances (the Welch-Aspin test) and was triangulated using bootstrapping. Both approaches gave the same statistical conclusions. A two-group Kaplan-Meier analysis of overall survival (OS) using the Mantel Cox log-rank test to judge statistical significance was conducted using a median cut-point on each of BCKDC (median = 0.6), hBCATm (median = 0.40), and hBCATc (median = 0.40). A two-group Kaplan-Meier analysis is robust to the presence of potentially influential observations. In addition, a sensitivity analysis was also performed to ensure conclusions were robust to the choice of cut-point.
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RESULTS
All IDH-WT tumours examined have increased expression of the BCAA metabolic proteins relative to normal brain tissue (Hull et al., 2012) . Western blot analysis has demonstrated that in IDH-WT tumours there was a significant increase in the expression of hBCATm (p=0.036) and hBCATc (p=0.007) relative to IDH mutation glioblastomas ( Figure 1A and B).
This increase in hBCAT expression was supported using IHC analysis ( Figure 1C ). Figure 2C ) and log-rank analysis shows that low hBCATm is significantly associated with better overall survival (p=0.043). The overall summary from these analyses is that hBCATm retains clinical utility across all data. Neither hBCATc nor BCKDC had a statistical effect on patient survival (p=0.971 and 0.642, respectively).
Moreover, between tumour grades we observed a significant increase in hBCATm expression (p=0.010), indicating that as expression of hBCAT increases prognosis is poorer ( Figure 3 ). Multiple banding patterns for hBCATm are also reported for anaplastic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w
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